Navigation Links
Rapid Increase In Sclerosant Use Will Drive Steady Expansion Of US Varicose Vein Treatment Device Market
Date:4/4/2013

TORONTO, April 4, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, growth in the United States market for varicose vein treatment devices will be driven largely by strong growth in the sclerotherapy market segment. Although endovenous ablation devices will continue to generate the most revenue in the varicose vein treatment device market, the sclerotherapy segment will see the strongest market growth; this segment will account for more than a quarter of the total market revenue by 2021.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO)

Sclerotherapy agents are versatile and can be applied either as a foam or a liquid. These procedures are also relatively easy for physicians to learn and perform. As a result, many non-surgeons are beginning to adopt these procedures over other treatments, such as endovenous ablation or phlebectomy. In particular, the foam sclerotherapy segment has historically been underpenetrated, and the efficiency, low cost and minimum invasiveness of this procedure will set the stage for rapid adoption through 2021.

The launch of BTG's Varisolve foam sclerosant in mid-2014 will further drive adoption in this segment. This product will represent the first US Food and Drug Administration (FDA)-approved foam sclerosant, and the high profile of this agent will further encourage physicians to use sclerosants over other treatment methods.

"The presence of an FDA-approved foam sclerosant on the market will boost the reputation of these procedures," says MRG Analyst Tonya Martin . "The launch of Varisolve will drive the use of foam for both on-label and off-label procedures, increasing the proportion of physicians using sclerotherapy. It's more rigorously tested and more convenient than the various 'homebrew' foam formulations physicians have been using, so we'll see strong uptake and revenue growth."

Although sclerotherapy will cannibalize sales in the phlebectomy segment, high sclerosant selling prices and strong procedure volume growth will support the steady expansion of the United States market for varicose vein treatment devices through 2021.

Millennium Research Group's US Markets for Varicose Vein Treatment Devices 2013 report includes unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for endovenous ablation devices, surgical stripping devices, phlebectomy devices and sclerotherapy agents in the United States.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com

Alex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Assurex Health Appoints Chief Financial Officer and Payer Market Executive to Manage Rapid Growth in Personalized Medicine
2. Independent Study Published in Clinical Infectious Diseases Highlights the Importance of Antimicrobial Removal Systems in Blood Culture to Rapidly and Accurately Aid in the Diagnosis of Sepsis
3. Fuisz Pharma Announces Patent Allowance For New Tablet And Caplet Shapes That Promote Rapid, Reliable Esophageal Transit
4. Frost & Sullivan: U.S. Health Information Exchange Market Enters Prime Time in Rapidly Transforming Healthcare Industry
5. Abacus Diagnostica Receives CE Mark for its Rapid Direct PCR Test for Toxigenic Clostridium Difficile
6. Artificial disc brings increased mobility and rapid recovery to patients suffering chronic neck pain in the Midwest
7. Epidemiology: Rheumatoid Arthritis in China - Rapid urbanization presents favorable market potential
8. Biodel Announces Phase 2 Clinical Trial Initiation Of Ultra-Rapid-Acting Insulin Candidate BIOD-123
9. Central Logic Poised for Rapid Expansion with New Financial Partner Mercato Partners
10. UK Hospitals Commence Advanced Stereotactic Lung Cancer Treatments Using RapidArc Radiosurgery
11. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):